JP2022529315A - 眼障害を処置するための化合物および方法 - Google Patents

眼障害を処置するための化合物および方法 Download PDF

Info

Publication number
JP2022529315A
JP2022529315A JP2021559179A JP2021559179A JP2022529315A JP 2022529315 A JP2022529315 A JP 2022529315A JP 2021559179 A JP2021559179 A JP 2021559179A JP 2021559179 A JP2021559179 A JP 2021559179A JP 2022529315 A JP2022529315 A JP 2022529315A
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
solvate
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021559179A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529315A5 (https=
Inventor
ホームズ，イアン
アルスター，ヤイル
バラッシュ，ヒラ
ボスワース，チャールズ
ラファエリ，オマー
グリーソン，マルク
スチュワート，マーク，リチャード
ダン，ジョナサン
エム． ブルク，ロバート
Original Assignee
アズーラ オフサルミックス エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アズーラ オフサルミックス エルティーディー． filed Critical アズーラ オフサルミックス エルティーディー．
Publication of JP2022529315A publication Critical patent/JP2022529315A/ja
Publication of JP2022529315A5 publication Critical patent/JP2022529315A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2021559179A 2019-04-18 2020-04-16 眼障害を処置するための化合物および方法 Pending JP2022529315A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962835975P 2019-04-18 2019-04-18
US62/835,975 2019-04-18
US202062966482P 2020-01-27 2020-01-27
US62/966,482 2020-01-27
PCT/IB2020/000312 WO2020212760A2 (en) 2019-04-18 2020-04-16 Compounds and methods for the treatment of ocular disorders

Publications (2)

Publication Number Publication Date
JP2022529315A true JP2022529315A (ja) 2022-06-21
JP2022529315A5 JP2022529315A5 (https=) 2023-04-24

Family

ID=72837068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559179A Pending JP2022529315A (ja) 2019-04-18 2020-04-16 眼障害を処置するための化合物および方法

Country Status (9)

Country Link
US (2) US11643429B2 (https=)
EP (1) EP3955937A4 (https=)
JP (1) JP2022529315A (https=)
KR (1) KR20210154214A (https=)
CN (1) CN114007625A (https=)
AU (1) AU2020259997B2 (https=)
CA (1) CA3136369A1 (https=)
IL (1) IL287280A (https=)
WO (1) WO2020212760A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3955937A4 (en) 2019-04-18 2023-01-18 Azura Ophthalmics Ltd. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
JP7700045B2 (ja) 2019-04-18 2025-06-30 アズーラ オフサルミックス エルティーディー． 眼障害を処置するための化合物および方法
IL302173A (en) * 2020-10-21 2023-06-01 Azura Ophthalmics Ltd Compounds and methods for the treatment of ocular disorders
CN116940570A (zh) * 2020-10-21 2023-10-24 阿祖拉眼科有限公司 用于治疗眼部病症的化合物和方法
EP4419502A4 (en) * 2021-10-20 2025-10-29 Azura Ophthalmics Ltd COMPOUNDS AND METHODS FOR THE TREATMENT OF SKIN AND OCULAR DISORDERS
TW202421700A (zh) 2022-07-28 2024-06-01 日商住友化學股份有限公司 偏光膜的製造方法及製造裝置
WO2024101918A1 (ko) * 2022-11-11 2024-05-16 주식회사 메디치바이오 리포-하이드록삼산 유도체 및 이의 약학적 용도
WO2024134266A1 (en) * 2022-12-20 2024-06-27 Azura Ophthalmics Ltd. Compounds and methods for the treatment of dermal and ocular disorders
WO2025012700A2 (en) * 2023-07-07 2025-01-16 Azura Ophthalmics Ltd. Compositions and methods for the treatment of autoimmune disorders

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01193292A (ja) * 1982-07-19 1989-08-03 Pfizer Inc Ｎ−メチル１１−アザ−１０−デオキソ−１０−ジヒドロエリスロマイシンａ製造用中間体
JP2001139591A (ja) * 1999-11-18 2001-05-22 Pfizer Prod Inc 新規マクロライド
CN1837225A (zh) * 2005-08-23 2006-09-27 济南思创生物技术有限公司 阿奇霉素衍生物及其制法和药物应用
JP2010534709A (ja) * 2007-07-30 2010-11-11 グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオ ９−デオキソ−９ａ−メチル−９ａ−アザ−９ａ−ホモエリスロマイシンＡ誘導体およびマラリアを治療するためのそれらの使用
JP2012516305A (ja) * 2009-01-30 2012-07-19 グラクソ グループ リミテッド 好中球優位の炎症性疾患の治療のための９−デオキソ−９ａ−メチル−９ａ−アザ−９ａ−ホモエリスロマイシンａ誘導体
WO2018161039A1 (en) * 2017-03-03 2018-09-07 Synovo Gmbh Novel anti-infective and anti-inflammatory compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350839A (en) * 1990-10-15 1994-09-27 Taisho Pharmaceutical Co., Ltd. 2'-position modified compound of erythromycin or its derivative
WO1995018604A1 (en) * 1994-01-11 1995-07-13 Ciba-Geigy Ag Topical treatment of ocular photophobia
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
RU2263117C2 (ru) * 2001-04-27 2005-10-27 Пфайзер Продактс Инк. Способ получения 4"-замещенных производных 9-деоксо-9а-аза-9а-гомоэритромицина а
FR2832637B1 (fr) * 2001-06-07 2004-07-30 Lefaix Marie Therese Droy Utilisation d'un antioxydant pour la fabrication d'un medicament destine au traitement des affections oculaires de surface
AU2003219770B2 (en) * 2002-02-15 2008-10-09 Merckle Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
GB0310984D0 (en) * 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
GB0310962D0 (en) * 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
GB0310980D0 (en) * 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
GB0609373D0 (en) * 2006-05-11 2006-06-21 Glaxo Group Ltd Macrolones
WO2011100769A2 (en) * 2010-02-15 2011-08-18 Synovo Gmbh Kinase modulators for the treatment of cancer
CA2840626A1 (en) * 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
AU2013239679A1 (en) * 2012-03-27 2014-10-30 Michael W. BURNET Anti-inflammatory macrolides
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
JP2019513775A (ja) 2016-04-19 2019-05-30 アズーラ オフサルミックス エルティーディー． 角化症の処置のための組成物
EP3600272A4 (en) 2017-03-29 2021-01-13 Azura Ophthalmics Ltd. MEANS OF INCREASING LIPID SECRETION OF THE MEIBOMAN GLAND
WO2018215638A1 (en) * 2017-05-26 2018-11-29 Novaliq Gmbh Pharmaceutical compositions comprising azithromycin
EP3955937A4 (en) 2019-04-18 2023-01-18 Azura Ophthalmics Ltd. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01193292A (ja) * 1982-07-19 1989-08-03 Pfizer Inc Ｎ−メチル１１−アザ−１０−デオキソ−１０−ジヒドロエリスロマイシンａ製造用中間体
JP2001139591A (ja) * 1999-11-18 2001-05-22 Pfizer Prod Inc 新規マクロライド
CN1837225A (zh) * 2005-08-23 2006-09-27 济南思创生物技术有限公司 阿奇霉素衍生物及其制法和药物应用
JP2010534709A (ja) * 2007-07-30 2010-11-11 グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオ ９−デオキソ−９ａ−メチル−９ａ−アザ−９ａ−ホモエリスロマイシンＡ誘導体およびマラリアを治療するためのそれらの使用
JP2012516305A (ja) * 2009-01-30 2012-07-19 グラクソ グループ リミテッド 好中球優位の炎症性疾患の治療のための９−デオキソ−９ａ−メチル−９ａ−アザ−９ａ−ホモエリスロマイシンａ誘導体
WO2018161039A1 (en) * 2017-03-03 2018-09-07 Synovo Gmbh Novel anti-infective and anti-inflammatory compounds

Also Published As

Publication number Publication date
IL287280A (en) 2021-12-01
EP3955937A4 (en) 2023-01-18
WO2020212760A2 (en) 2020-10-22
KR20210154214A (ko) 2021-12-20
AU2020259997B2 (en) 2025-08-07
AU2020259997A1 (en) 2021-11-25
CA3136369A1 (en) 2020-10-22
US20230348517A1 (en) 2023-11-02
US11643429B2 (en) 2023-05-09
US20210230205A1 (en) 2021-07-29
WO2020212760A3 (en) 2021-02-25
CN114007625A (zh) 2022-02-01
EP3955937A2 (en) 2022-02-23

Similar Documents

Publication Publication Date Title
JP2022529315A (ja) 眼障害を処置するための化合物および方法
JP7700045B2 (ja) 眼障害を処置するための化合物および方法
JP2023546453A (ja) 眼障害を処置するための化合物および方法
AU2020259996B2 (en) Compounds and methods for the treatment of ocular disorders
JP2023546915A (ja) 眼障害を処置するための化合物および方法
US20250042931A1 (en) Compounds and methods for the treatment of ocular disorders
JP2023546452A (ja) 眼障害を処置するための化合物および方法
CN116940570A (zh) 用于治疗眼部病症的化合物和方法
HK40068817A (en) Compounds and methods for the treatment of ocular disorders
HK40068671A (en) Compounds and methods for the treatment of ocular disorders
JP2024538954A (ja) 皮膚および眼の障害を処置するための化合物および方法
HK40100091A (zh) 用於治疗眼部病症的化合物和方法
HK40100700A (zh) 用於治疗眼部病症的化合物和方法
HK40102653A (zh) 用於治疗眼部病症的化合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211109

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250728

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260324